Abstract
No public abstract is available from the verified source records.
Philippe L. Bedard, Chantal Bernard-Marty, Cristina Raimondi, Fátima Cardoso
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women
10.1186/bcr1672 · 2007
Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis
10.1200/jco.2006.09.2106 · 2007
Time trends in systemic adjuvant treatment for node-negative breast cancer
10.1200/jco.1999.17.5.1458 · 1999
Individual patient- versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer
10.1016/s0197-2456(01)00152-0 · 2001
Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden
10.1371/journal.pmed.0030025 · 2006
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
10.1200/jco.1999.17.2.485 · 1999
Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · 2001
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
10.1093/annonc/mdg346 · 2003
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
10.1016/j.ejca.2003.11.007 · 2004
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
10.1200/jco.2005.05.098 · 2005
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
10.1200/jco.2007.12.6557 · 2007
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
10.1007/s10549-010-0901-4 · 2010
A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)
2007
Unresolved referenced work
2001
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
10.1200/jco.2005.02.167 · 2005
Capecitabine monotherapy for elderly patients with metastatic breast cancer
10.1200/jco.2004.22.14_suppl.797 · 2004
Phase II study of capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC): final results
10.1200/jco.2006.24.18_suppl.10709 · 2006
Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)
10.1200/jco.2007.25.18_suppl.1080 · 2007
Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >=75years old with metastatic breast cancer
10.1016/s1359-6349(08)70731-6 · 2008
Randomized, open-label, phase II trial of oral capecitabine (Xeloda(R)) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
10.1023/a:1012281104865 · 2001
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
10.1200/jco.2002.09.002 · 2002
(OS) in patients with metastatic breast cancer (MBC) treated with capecitabine [abstract 1097]
2009
Docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with advanced breast cancer. Final results of a multicenter phase III trial (abstract 136O)
2008
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
10.1200/jco.2007.15.8485 · 2009
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
10.1200/jco.2005.05.1383 · 2006
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
10.1038/sj.bjc.6601784 · 2004
Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group
10.1200/jco.2006.24.18_suppl.517 · 2006
Capecitabine and vinorelbine in metastatic breast cancer
10.1016/j.ejca.2009.04.031 · 2009
Capecitabine (C) and vinorelbine (V) in elderly patients (pts) with metastatic breast cancer (MBC) as first line treatment: a prospective multicentre phase II study of the NOGGO breast cancer study group
2006
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
10.1159/000127414 · 2007
Capecitabine and vinorelbine in elderly patients (> or =65years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
10.1093/annonc/mdh467 · 2004
Dose-escalated vinorelbine-capecitabine in elderly metastatic breast cancer patients. A SICOG phase II study (abstract 155P)
2006
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study
10.1200/jco.2008.19.6618 · 2009
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
10.1007/s10549-007-9885-0 · 2008
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
10.1200/jco.2009.27.15_suppl.1005 · 2009
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
10.1016/s0140-6736(05)66544-0 · 2005
Adjuvant chemotherapy in older women with early-stage breast cancer
10.1056/nejmoa0810266 · 2009
CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907
10.1200/jco.2008.26.15_suppl.6542 · 2008
A feasability study of capecitabine monotherapy for elderly patients with high risk early breast cancer
2007
Comprehensive geriatric assessment for older patients with cancer
10.1200/jco.2007.10.6559 · 2007
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO)
10.1016/j.critrevonc.2009.12.003 · doi-reference
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
10.1111/j.1532-5415.2006.00789.x · doi-reference
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
10.1093/jnci/95.5.362 · doi-reference
Update on drug-related problems in the elderly
10.1016/s1543-5946(03)80014-4 · doi-reference
Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey
10.1001/jama.286.22.2823 · doi-reference
Understanding and preventing drug interactions in elderly patients
10.1016/j.critrevonc.2003.04.004 · doi-reference
Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay
10.1093/gerona/61.5.511 · doi-reference
Adverse drug events in ambulatory care
10.1056/nejmsa020703 · doi-reference
Estimating renal function in older people: a comparison of three formulas
10.1093/ageing/afj041 · doi-reference
Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people
10.1093/ageing/afm121 · doi-reference
Prediction of creatinine clearance from serum creatinine
10.1159/000180580 · doi-reference
Estimating the prevalence of renal insufficiency in seniors requiring long-term care
10.1111/j.1523-1755.2004.00412.x · doi-reference
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
10.1200/jco.2006.06.5391 · doi-reference
Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735
10.1200/jco.2008.18.4028 · doi-reference
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
10.1200/jco.2000.18.7.1412 · doi-reference
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
10.1200/jco.2006.10.4976 · doi-reference